查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830652

辅助生殖技术市场（按技术、週期类型、治疗、最终用户和产品划分）—2025-2032 年全球预测

Assisted Reproductive Technology Market by Technique, Cycle Type, Treatment, End User, Product - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年辅助生殖技术市场规模将成长至 1,115.1 亿美元，复合年增长率为 18.07%。

主要市场统计数据
基准年2024年 295.2亿美元
预计2025年 347.6亿美元
预测年份：2032年 1115.1亿美元
复合年增长率（%） 18.07%

塑造辅助生殖技术服务和相关人员优先事项的临床、营运和商业性动态的简明策略框架

辅助生殖技术正在快速发展，相关人员需要重新思考关于临床实践、商业模式和病人历程的假设。新的检测技术、不断扩展的医疗服务网络以及不断变化的患者期​​望正在共同重塑医疗服务。因此，临床、诊断、设备和相关服务领域的领导者必须综合考虑医疗、监管和商业性讯号，才能做出及时、基于证据的决策。

本执行摘要概述了影响医疗保健提供者、产品开发者、付款人和投资者的核心动态。它重点关注临床程序分布、治疗途径的细微差别、产品和服务差异化以及最终用户的采用模式。它以技术、週期类型、治疗方式、最终用户和产品线为框架，提供了一个连贯的观点，探讨临床进展和系统层面的力量如何相互作用，从而创造新的机会和营运挑战。其目的是提供一个策略视角，以支持在不确定性下进行决策，同时展示哪些短期行动可以带来重大价值。

科学突破、业务整合和数位创新如何重塑辅助生殖技术的临床路径和商业模式

在科学创新、营运整合和以病人为中心的护理模式的推动下，辅助生殖技术领域正在经历一场变革性的转变。基因检测和胚胎选择方法的进步正在优化临床路径，降低週期变异性，并提升术前诊断的重要性。同时，实验室自动化和冷冻保存化学技术的进步使诊所能够简化流程，并提高治疗之间的可重复性。

在营运方面，生育服务提供者之间的整合以及门诊手术中心与医院系统之间合作的加强，正在创造新的转诊模式和规模优势。私募股权和策略投资者持续重塑市场，推动护理通讯协定的标准化和实验室服务的集中化。同时，数位健康平台正在简化患者入院、远端监控和数据采集流程，帮助诊所提高依从性和临床疗效。监管监督和付款人参与正在适应这些变化，强调品质指标、真实世界证据和成本效益。

评估近期关税变化和贸易动态如何再形成辅助生殖技术供应链的采购、製造足迹和成本管理策略

不断变化的关税政策和国际贸易动态正在对辅助生殖技术组件和设备的供应链产生累积影响。进口关税影响专用检测设备、显微镜、培养箱和冷冻保存系统的到岸成本，而试剂和培养基的关税则影响诊所和中心实验室的经常性运作成本。因此，采购实务正在转向多元化筹资策略，并更加重视与具有弹性物流能力的供应商建立伙伴关係。

製造商和服务供应商正在透过重新评估其生产基地、提高关键零件的本地化程度以及协商包含关税意外事件的供应合约来应对这一挑战。诊所和实验室正在修改其融资时间表，并寻求灵活的资金筹措结构以缓解短期成本上涨。此外，一些相关人员正在加快对国内製造或区域配送中心的投资，以降低跨境关税波动带来的风险。总的来说，这些调整措施将缓解短期营运中断，但要在维持医疗品质的同时控製成本，需要采购、临床领导层和商业策略之间进行更长期的协调。

利用多方面的细分，优先考虑技术、週期类型、疗法、最终用户和产品类型的产品开发、临床支援和商业性方法

基于细分市场的深入分析揭示了临床技术、週期类型、治疗方式、最终用户环境和产品类型各自构成不同的商业性需求和应用障碍。配子输卵管植入、体外受精、卵细胞质内单一精虫显微注射术、子宫内人工授精和受精卵输卵管植入等技术在资源强度、技术人员技能需求和实验室基础设施需求方面各不相同。就週期类型而言，新鲜供体、新鲜非供体和冷冻保存方法之间的差异会影响治疗时间、冷冻保存需求和患者咨询优先级，从而促使诊所製定差异化的运作方案。

对冷冻保存、胚胎移植、基因检测和卵子等治疗类别进行评估，可以发现专业化和捆绑服务的机会。最终使用者环境（包括门诊手术中心、生育诊所和医院）呈现不同的资本结构、法律规范和病患吞吐量限制，这些都会影响新设备和耗材的投资週期。最后，将产品细分为耗材、设备、培养基和试剂以及服务，可以揭示不同的利润状况和创新方向。耗材和培养基需要频繁补货和遵守法规，而设备和服务则代表高额投资，部署週期很长。总之，这些细分使相关人员能够优先考虑产品开发、确定商业化策略并客製化临床支援模型，以最大限度地提高临床价值和营运效率。

美洲、中东和非洲以及亚太地区的法规环境、临床专业知识分布和病患需求模式如何创造差异化机会

区域动态显着影响辅助生殖技术的临床实务模式、投资意愿和监管趋势。美洲拥有丰富的公私医疗资金、竞争激烈的诊所网络、强劲的患者需求以及充满活力的风险投资支持的创新格局，专业实验室能力集中在都市区。欧洲、中东和非洲的管理体制和报销框架各不相同，影响市场进入以及先进诊断和实验室自动化的采用曲线。跨境合作和医疗旅游也会影响专业服务的提供地点。亚太地区的特点是产能扩张迅速、临床专业化程度不断提高以及监管成熟度参差不齐，这为能够适应当地临床工作流程和价格敏感度的国内供应商和跨国公司创造了机会。

这些区域差异直接影响供应链设计、商业性伙伴关係和临床培训计画。开发商和服务供应商在製定特定区域的价值提案时，必须兼顾不同的认证要求、进口法规和付款人期望。此外，不同区域的患者偏好和文化因素会影响对週期类型和治疗方式的需求，进而影响诊所建立护理路径和与患者互动的策略。因此，有效的区域规划，结合监管远见、本地伙伴关係和适应文化的患者支持，可以加速采用并维持长期临床效果。

透过产品可靠性、整合临床工作流程和服务主导的实施策略来定义竞争动态，以加速不孕症护理领域的技术接受度

辅助生殖技术生态系统中各公司之间的竞争动态反映了临床可靠性、产品创新和策略服务伙伴关係之间的平衡。领先的仪器製造商和实验室解决方案提供商在可靠性、易用性和降低实验室差异性的整合工作流程方面各有千秋。耗材和培养基供应商则在配方稳定性、法规遵循性和供应连续性方面竞争。服务型公司越来越多地将培训、远端监控和实验室品质保证捆绑在一起，以支援诊所的采用并降低其扩大病例量的营运风险。

临床医生与商业团队之间的策略合作仍然是产品改进的关键驱动力。早期采用者可作为检验新方法的参考点，而其他采用者则透过与门诊手术中心和医院系统的合作实现规模化，将技术嵌入现有的护理路径中。最有效的市场参与企业将结合卓越的技术、强大的售后支援、明确的监管立场，以及展示工作流程效率的能力，从而为医疗服务提供者带来可衡量的临床或经济效益。

为企业提供实际的策略行动，以加强临床伙伴关係、供应弹性、整合产品和区域上市效率

产业领导者应采取一系列重点行动，在维护临床诚信和病患疗效的同时，确保竞争优势。首先，优先与高绩效诊所伙伴关係，共同製定方案并产生真实世界证据，以强化产品价值提案。透过使产品开发週期与临床医生的需求保持一致，公司可以缩短产品上市时间，并增强临床医生对新治疗方法的信心。其次，投资于供应链弹性以及区域製造和分销能力，可以减轻贸易中断和关税变化的影响，并保护净利率和服务连续性。

第三，采用整合的商业模式，将器械、耗材和临床导向服务（例如培训和品管）结合起来，创建捆绑产品，简化最终用户的采购和上线流程。第四，调整区域市场策略，以反映当地的监管、文化和付款人环境，使定价、报销支援和病患沟通与市场实际情况相符。最后，投入资源用于数位化赋能，例如病人参与平台、远端监控和数据分析，以提高依从性、优化吞吐量，并产生纵向证据来支持临床和经济价值主张。这些措施共同作用，使组织能够灵活应对市场变化，并充分利用临床和营运方面的进步。

这些见解背后的调查方法结合了对临床文献、监管文件和公开指南的结构化综述，以及对临床医生、实验室主任和公司高管的定性访谈。证据综合研究优先考虑高品质的临床研究、专业协会共识声明和监管趋势文件，以确保结论反映当前的实践模式和管治预期。访谈资料用于检验营运假设、了解采购行为，并揭示正式出版物中可能尚未涵盖的新兴产品偏好。

分析方法包括对技术、週期类型、疗法、最终用户和产品细分进行比较评估，以揭示差异化的驱动因素和应用障碍。区域分析纳入了监管影响、报销细则和容量指标，以阐明商业性影响。自始至终，我们专注于将来自文献资讯来源的定量讯号与领域专家的定性观察相结合，以形成可行的观点，同时承认持续存在的不确定性领域以及持续证据监测的必要性。

整合临床、营运和商业性需求，以确定不断发展的辅助生殖技术生态系统中的永续竞争优势

总而言之，辅助生殖技术正处于曲折点，临床创新、操作复杂度和市场动态正在汇聚，从而催生出差异化的赢家。特定技术需求、週期类型偏好、治疗方式、最终用户能力和产品定位的相互作用，将决定谁能在市场发展过程中获得价值。积极主动地将临床证据产生与弹性供应策略和整合服务模式结合的相关人员，将最有能力在负责任地扩展业务的同时，提供一致的成果。

因此，决策者应优先考虑能够加速真实世界检验的伙伴关係，投资于区域供应的连续性，并采用能够简化供应商采用的商业性方法。透过专注于这些优先事项，医疗保健组织可以改善患者照护，并在临床可靠性和卓越营运至关重要的领域建立可辩护的商业性提案。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 越来越多地采用胚胎着床前基因检测来评估胚胎健康并制定个人化移植策略
  • 扩展家用生育监测套件，利用人工智慧驱动的荷尔蒙追踪进行早期疗育
  • 整合区块链技术，确保病患资料安全并简化跨境卵子捐赠流程
  • 在为职业发展而推迟生育的专业人士中，社会卵子冷冻服务日益增多
  • 生育诊所和远端医疗平台越来越多地合作提供虚拟咨询和远距支持
  • 利用延时成像和AI预测分析来评估胚胎活力的非侵入性评估技术开发
  • 男性不孕症治疗激增，包括基因编辑研究和针对精子发生的分子诊断
  • 透过公私合营和行动诊所部署，在新兴市场扩大低成本 IVF 服务
  • 人们对为肿瘤患者整合新型冷冻保存介质和方法的生育力保存通讯协定的兴趣日益浓厚。
  • 推出数位健康平台，为整个辅助生殖週期提供个人化生育指导和情感支持

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 辅助生殖科技市场（依技术）

  • 配子输卵管植入
  • 体外受精
    • 新捐款者
    • 新的非捐赠者
    • 冷冻
  • 卵细胞质内单一精虫显微注射术
  • 子宫内人工授精
  • 受精卵输卵管内移植

9. 辅助生殖技术市场（依週期类型）

  • 新捐款者
  • 新的非捐赠者
  • 冷冻

第十章辅助生殖科技市场（依治疗）

  • 冷冻保存
  • 胚胎移植
  • 基因检测
  • 卵子收集

第 11 章辅助生殖技术市场（按最终用户划分）

  • 门诊手术中心
  • 不孕不育诊所
  • 医院

第十二章辅助生殖技术市场（按产品）

  • 耗材
  • 装置
  • 培养基和试剂
  • 服务

第 13 章：辅助生殖科技市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章辅助生殖技术市场（按群体）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国辅助生殖技术市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • CooperCompanies, Inc.
    • Vitrolife AB
    • FUJIFILM Irvine Scientific, Inc.
    • Charles River Laboratories International, Inc.
    • Progyny, Inc.
    • Hamilton Thorne Ltd.
    • Ovascience, Inc.
    • Cryo-Cell International, Inc.
Product Code: MRR-436901065A94

The Assisted Reproductive Technology Market is projected to grow by USD 111.51 billion at a CAGR of 18.07% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 29.52 billion
Estimated Year [2025] USD 34.76 billion
Forecast Year [2032] USD 111.51 billion
CAGR (%) 18.07%

Concise strategic framing of clinical, operational, and commercial dynamics reshaping assisted reproductive technology services and stakeholder priorities

Assisted reproductive technology is evolving at a pace that requires stakeholders to revisit assumptions about clinical practice, commercial models, and patient journeys. Emerging laboratory techniques, expanding provider networks, and shifting patient expectations are converging to reshape care delivery. As a result, leaders across clinical, diagnostic, equipment, and adjacent service segments must synthesize medical, regulatory, and commercial signals to make timely, evidence-based decisions.

This executive summary synthesizes core dynamics affecting practitioners, product developers, payers, and investors. It focuses on clinical technique distribution, treatment pathway nuances, product and service differentiation, and end-user adoption patterns. By framing the discussion around technique, cycle type, treatment modality, end-user, and product lines, the narrative offers a cohesive perspective on how clinical advances and system-level forces are interacting to create new opportunities and operational challenges. The aim is to provide a strategic lens that supports decision-making under uncertainty, while signalling where near-term action can deliver outsized value.

How scientific breakthroughs, operational consolidation, and digital innovations are jointly reshaping clinical pathways and commercial models in assisted reproduction

The landscape of assisted reproductive technology is experiencing transformative shifts driven by scientific innovation, operational consolidation, and patient-centric care models. Advances in genetic testing and embryo selection methods are refining clinical pathways, reducing cycle variability, and increasing the emphasis on pre-procedural diagnostics. Concurrently, laboratory automation and improvements in cryopreservation chemistry are enabling clinics to streamline throughput and enhance reproducibility across treatments.

Operationally, consolidation among fertility providers and increased collaboration between ambulatory surgical centers and hospital systems are creating new referral patterns and scale advantages. Private equity and strategic investors continue to reshape the marketplace, prompting standardization of care protocols and the emergence of centralized laboratory services. In parallel, digital health platforms are simplifying patient onboarding, remote monitoring, and data capture, which is helping clinics improve adherence and clinical outcomes. Regulatory scrutiny and payer engagement are adapting to these changes, emphasizing quality metrics, real-world evidence, and cost-effectiveness, which collectively alter how new technologies are adopted and reimbursed.

Assessment of how recent tariff changes and trade dynamics are reshaping procurement, manufacturing footprints, and cost management strategies across the assisted reproduction supply chain

Tariff policy changes and international trade dynamics are exerting cumulative effects on the supply chain for assisted reproductive technology components and equipment. Import duties can influence the landed cost of specialized laboratory equipment, microscopes, incubators, and cryogenic storage systems, while tariffs on reagents and media affect recurring operational expenditures for clinics and centralized labs. As a consequence, procurement practices are shifting toward diversified sourcing strategies and increased emphasis on vendor partnerships with resilient logistics capabilities.

Manufacturers and service providers are responding by re-evaluating production footprints, increasing localization of critical components, and negotiating supply contracts that incorporate tariff contingencies. Clinics and laboratories are reassessing capital acquisition timelines and exploring flexible financing structures to mitigate near-term cost escalations. In addition, some stakeholders are accelerating investments in domestic manufacturing or regional distribution hubs to reduce exposure to cross-border tariff volatility. These adaptive measures collectively dampen immediate operational disruption but require longer-term alignment between procurement, clinical leadership, and commercial strategy to sustain cost control while preserving quality of care.

Leveraging multidimensional segmentation to prioritize product development, clinical support, and commercial approaches across technique, cycle type, treatment, end user, and product categories

Insightful segmentation-based analysis illuminates how clinical techniques, cycle types, treatment modalities, end-user settings, and product categories each drive distinct commercial imperatives and adoption barriers. Across techniques such as gamete intrafallopian transfer, in vitro fertilization, intracytoplasmic sperm injection, intrauterine insemination, and zygote intrafallopian transfer, practices vary in resource intensity, technician skill requirements, and laboratory infrastructure needs, with in vitro fertilization representing a focal point given its procedural complexity and breadth of clinical pathways that include fresh donor, fresh non-donor, and frozen cycles. Considering cycle type, the distinctions among fresh donor, fresh non-donor, and frozen approaches influence scheduling, cryostorage demand, and patient counseling priorities, prompting clinics to develop differentiated operational playbooks.

When evaluated through the lens of treatment categories such as cryopreservation, embryo transfer, genetic testing, and oocyte retrieval, opportunities for specialization and service bundling become apparent, particularly where genetic testing can be integrated early in the patient journey to inform downstream clinical decisions. End-user environments-spanning ambulatory surgical centers, fertility clinics, and hospitals-present varying capital structures, regulatory oversight, and patient throughput constraints that affect investment cycles for new equipment and consumables. Lastly, product segmentation into consumables, equipment, media and reagents, and services highlights divergent margin profiles and innovation vectors; consumables and media demand frequent replenishment and regulatory compliance, whereas equipment and services represent higher-ticket investments with extended adoption timelines. Taken together, these segmentation dimensions enable stakeholders to prioritize product development, target commercialization strategies, and tailor clinical support models to maximize clinical value and operational efficiency.

How regional regulatory environments, clinical expertise distribution, and patient demand patterns create differentiated opportunities across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are materially shaping clinical practice patterns, investment appetite, and regulatory trajectories in assisted reproductive technologies. In the Americas, a mix of private and public healthcare funding drives competitive clinic networks, strong patient demand, and active venture-backed innovation, with urban centers concentrating specialized laboratory capabilities. Europe, Middle East & Africa displays heterogenous regulatory regimes and reimbursement frameworks that influence market entry and the adoption curve for advanced diagnostics and laboratory automation; cross-border collaboration and medical tourism also affect where specialized services are delivered. Asia-Pacific is characterized by rapid capacity expansion, rising clinical expertise, and varying levels of regulatory maturity, creating opportunities for both domestic suppliers and multinational firms that can adapt to local clinical workflows and price sensitivities.

These regional distinctions have direct implications for supply chain design, commercial partnerships, and clinical training programs. Manufacturers and service providers must navigate distinct certification requirements, import regulations, and payer expectations while developing localized value propositions. Moreover, regional patient preferences and cultural considerations shape demand for cycle types and treatment modalities, which in turn influence how clinics structure care pathways and patient engagement strategies. Effective regional plans therefore combine regulatory foresight, local partnerships, and culturally attuned patient support to accelerate adoption and sustain long-term clinical outcomes.

Competitive dynamics defined by product reliability, integrated clinical workflows, and service-led adoption strategies that accelerate technology acceptance in fertility care

Competitive dynamics among companies operating in the assisted reproductive technology ecosystem reflect a balance between clinical credibility, product innovation, and strategic service partnerships. Leading equipment manufacturers and laboratory solution providers differentiate through reliability, ease of use, and integrated workflows that reduce laboratory variability. Consumable and media suppliers compete on formulation stability, regulatory compliance, and supply continuity, as reproducible performance directly affects clinical outcomes. Service-oriented firms are increasingly bundling training, remote monitoring, and laboratory quality assurance to support adoption and mitigate operational risk for clinics expanding their case volumes.

Strategic collaboration between clinicians and commercial teams continues to be a major driver of product refinement, with early adopters serving as reference sites that validate new approaches. Meanwhile, some companies are scaling through partnerships with ambulatory surgical centers and hospital systems to embed technology into established care pathways. The most effective market participants combine technical excellence with robust post-sale support, clear regulatory positioning, and an ability to demonstrate workflow efficiencies that translate into measurable clinical or economic benefits for provider organizations.

Practical strategic actions for companies to enhance clinical partnership, supply resilience, integrated offerings, and regional go-to-market effectiveness

Industry leaders should pursue a focused set of actions to secure competitive advantage while preserving clinical integrity and patient outcomes. First, prioritize partnerships with high-performing clinics to co-develop protocols and to generate real-world evidence that reinforces product value propositions. By aligning product development cycles with clinician needs, companies can reduce time-to-adoption and increase practitioner confidence in new modalities. Second, invest in supply chain resilience and regional manufacturing or distribution arrangements to mitigate the effects of trade disruptions and tariff shifts, thereby protecting margins and service continuity.

Third, adopt integrated commercial models that combine equipment, consumables, and clinically oriented services such as training and quality management to create bundled offerings that simplify procurement and operational onboarding for end users. Fourth, tailor regional go-to-market strategies that reflect local regulatory, cultural, and payer environments, ensuring that pricing, reimbursement support, and patient communication are aligned with market realities. Finally, commit resources to digital enablement-patient engagement platforms, remote monitoring, and data analytics-to improve adherence, optimize throughput, and generate longitudinal evidence that supports both clinical and economic value claims. Collectively, these actions position organizations to respond nimbly to market shifts and to capitalize on clinical and operational advancements.

The research methodology underpinning these insights combines a structured review of clinical literature, regulatory materials, and publicly available guidance with qualitative interviews of clinicians, laboratory directors, and commercial executives. Evidence synthesis prioritized high-quality clinical studies, consensus statements from professional societies, and documentation of regulatory trends to ensure conclusions reflect current practice patterns and governance expectations. Interview data were used to validate operational assumptions, understand procurement behaviors, and surface emerging product preferences that may not yet be captured in formal publications.

Analytical approaches included comparative assessment across technique, cycle type, treatment, end-user, and product segmentation to reveal differentiation drivers and adoption barriers. Regional analysis incorporated regulatory pathways, reimbursement nuances, and capacity indicators to contextualize commercial implications. Throughout, emphasis was placed on triangulation-aligning quantitative signals from documented sources with qualitative observations from field experts-to produce actionable perspectives while acknowledging areas of ongoing uncertainty and the need for continuous evidence monitoring.

Synthesis of clinical, operational, and commercial imperatives that will determine sustainable competitive advantage in the evolving assisted reproductive technology ecosystem

In conclusion, assisted reproductive technology is at an inflection point where clinical innovation, operational sophistication, and market dynamics converge to create differentiated winners. The interplay between technique-specific demands, cycle type preferences, treatment modalities, end-user capabilities, and product positioning will determine who captures value as the market evolves. Stakeholders that proactively align clinical evidence generation with resilient supply strategies and integrated service models will be best positioned to deliver consistent outcomes while scaling responsibly.

Decision-makers should therefore prioritize partnerships that accelerate real-world validation, invest in regional supply continuity, and adopt commercial approaches that simplify adoption for providers. By focusing on these priorities, organizations can both improve patient care and establish defensible commercial propositions in a sector where clinical credibility and operational excellence are essential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of preimplantation genetic testing for embryo health assessment and personalized transfer strategies
  • 5.2. Expansion of at-home fertility monitoring kits leveraging AI-driven hormone tracking for early intervention
  • 5.3. Integration of blockchain technology to secure patient data and streamline cross-border egg donation processes
  • 5.4. Growth in social egg freezing services among working professionals delaying parenthood for career progression
  • 5.5. Rising collaborations between fertility clinics and telemedicine platforms to offer virtual consultations and remote support
  • 5.6. Development of noninvasive embryo evaluation techniques using time-lapse imaging and AI predictive analytics for viability scoring
  • 5.7. Surge in male fertility treatments incorporating gene editing research and targeted molecular diagnostics for spermatogenesis
  • 5.8. Expansion of low-cost IVF services in emerging markets through public-private partnerships and mobile clinic deployments
  • 5.9. Increasing focus on fertility preservation protocols for oncology patients integrating novel cryopreservation media and methods
  • 5.10. Adoption of digital health platforms for personalized fertility coaching and emotional support throughout assisted reproduction cycles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Assisted Reproductive Technology Market, by Technique

  • 8.1. Gamete Intrafallopian Transfer
  • 8.2. In Vitro Fertilization
    • 8.2.1. Fresh Donor
    • 8.2.2. Fresh Non-Donor
    • 8.2.3. Frozen
  • 8.3. Intracytoplasmic Sperm Injection
  • 8.4. Intrauterine Insemination
  • 8.5. Zygote Intrafallopian Transfer

9. Assisted Reproductive Technology Market, by Cycle Type

  • 9.1. Fresh Donor
  • 9.2. Fresh Non-Donor
  • 9.3. Frozen

10. Assisted Reproductive Technology Market, by Treatment

  • 10.1. Cryopreservation
  • 10.2. Embryo Transfer
  • 10.3. Genetic Testing
  • 10.4. Oocyte Retrieval

11. Assisted Reproductive Technology Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Fertility Clinics
  • 11.3. Hospitals

12. Assisted Reproductive Technology Market, by Product

  • 12.1. Consumables
  • 12.2. Equipment
  • 12.3. Media And Reagents
  • 12.4. Services

13. Assisted Reproductive Technology Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Assisted Reproductive Technology Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Assisted Reproductive Technology Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck KGaA
    • 16.3.2. Thermo Fisher Scientific Inc.
    • 16.3.3. CooperCompanies, Inc.
    • 16.3.4. Vitrolife AB
    • 16.3.5. FUJIFILM Irvine Scientific, Inc.
    • 16.3.6. Charles River Laboratories International, Inc.
    • 16.3.7. Progyny, Inc.
    • 16.3.8. Hamilton Thorne Ltd.
    • 16.3.9. Ovascience, Inc.
    • 16.3.10. Cryo-Cell International, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2024 (USD MILLION)
  • TABLE 282. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025-2032 (USD MILLION)
  • TABLE 283. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2024 (USD MILLION)
  • TABLE 284. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2025-2032 (USD MILLION)
  • TABLE 285. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 288. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 289. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. G